Related Experiment Videos
[The chemotherapy for hepatocellular carcinoma]
Hiroaki Nagano1, Masato Sakon, Morito Monden
1Departement of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, E-2, Suita, Osaka 565-0871, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 4, 2003
Summary
For advanced liver cancer (HCC) patients with cirrhosis, chemotherapy is challenging. A combination of subcutaneous interferon-alpha (IFN-alpha) and intraarterial 5-fluorouracil (5-FU) shows promise for difficult cases.
Area of Science:
- Oncology
- Hepatology
- Pharmacology
Context:
- Hepatocellular carcinoma (HCC) with liver cirrhosis presents treatment challenges due to poor liver function and low drug sensitivity.
- Standard therapies like resection and transarterial chemoembolization (TACE) may be ineffective for advanced HCC.
- Intraarterial chemotherapy is common but often lacks sufficient efficacy.
Purpose:
- To evaluate the effectiveness of novel combination therapies for advanced hepatocellular carcinoma (HCC).
- To explore treatment options for HCC patients with liver cirrhosis where conventional therapies fail.
Summary:
- A combination therapy involving subcutaneous interferon-alpha (IFN-alpha) and intraarterial 5-fluorouracil (5-FU) demonstrated a high effective rate in intractable HCC cases (Vp3).
- This regimen offers a potential improvement over standard intraarterial chemotherapy for specific HCC patient populations.
Impact:
- This combination therapy represents a promising treatment modality for advanced HCC, potentially improving patient prognosis.
- Further development and clinical validation are expected to advance HCC treatment strategies.